VYNE Therapeutics (NASDAQ:VYNE) Earns Buy Rating from HC Wainwright

VYNE Therapeutics (NASDAQ:VYNE)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $5.75 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 82.25% from the stock’s current price.

VYNE Therapeutics Stock Up 0.8 %

VYNE opened at $3.16 on Friday. VYNE Therapeutics has a twelve month low of $1.57 and a twelve month high of $4.48. The company has a 50-day simple moving average of $2.12 and a 200 day simple moving average of $2.16. The stock has a market capitalization of $46.53 million, a price-to-earnings ratio of -1.22 and a beta of 1.32.

VYNE Therapeutics (NASDAQ:VYNE) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). VYNE Therapeutics had a negative return on equity of 43.11% and a negative net margin of 5,849.18%. The firm had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.11 million. Sell-side analysts anticipate that VYNE Therapeutics will post -0.86 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Lynx1 Capital Management LP bought a new position in VYNE Therapeutics Inc. (NASDAQ:VYNE) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics comprises 0.0% of Lynx1 Capital Management LP’s portfolio, making the stock its 17th biggest holding. Lynx1 Capital Management LP owned approximately 0.11% of VYNE Therapeutics as of its most recent SEC filing. 83.78% of the stock is currently owned by institutional investors and hedge funds.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.